Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin
© Gurramkonda et al; licensee BioMed Central Ltd. 2010
Received: 27 January 2010
Accepted: 12 May 2010
Published: 12 May 2010
The prevalence of diabetes is predicted to rise significantly in the coming decades. A recent analysis projects that by the year 2030 there will be ~366 million diabetics around the world, leading to an increased demand for inexpensive insulin to make this life-saving drug also affordable for resource poor countries.
A synthetic insulin precursor (IP)-encoding gene, codon-optimized for expression in P. pastoris, was cloned in frame with the Saccharomyces cerevisiae α-factor secretory signal and integrated into the genome of P. pastoris strain X-33. The strain was grown to high-cell density in a batch procedure using a defined medium with low salt and high glycerol concentrations. Following batch growth, production of IP was carried out at methanol concentrations of 2 g L-1, which were kept constant throughout the remaining production phase. This robust feeding strategy led to the secretion of ~3 gram IP per liter of culture broth (corresponding to almost 4 gram IP per liter of cell-free culture supernatant). Using immobilized metal ion affinity chromatography (IMAC) as a novel approach for IP purification, 95% of the secreted product was recovered with a purity of 96% from the clarified culture supernatant. Finally, the purified IP was trypsin digested, transpeptidated, deprotected and further purified leading to ~1.5 g of 99% pure recombinant human insulin per liter of culture broth.
A simple two-phase cultivation process composed of a glycerol batch and a constant methanol fed-batch phase recently developed for the intracellular production of the Hepatitis B surface antigen was adapted to secretory IP production. Compared to the highest previously reported value, this approach resulted in an ~2 fold enhancement of IP production using Pichia based expression systems, thus significantly increasing the efficiency of insulin manufacture.
Diabetes is a progressive disease characterized by hyperglycemia, resulting from defects in insulin secretion, its function, or both. The long-term effects of this disease, for which there is no cure, lead to multiple organ damage and failure . The World Health Organization estimates that ~2.9 million deaths are attributable to diabetes every year . Based on demographic changes, it has been estimated that the number of diabetics around the world, which was ~171 million at the turn of this century, will more than double by the year 2030 . This is likely to be an underestimate given that factors, such as improved life expectancy and obesity contributing to increased prevalence of diabetes, have not been taken into consideration.
Insulin is a 51 amino acid (aa) polypeptide hormone essential for normal glucose homeostasis and is therefore useful in treating diabetes. Insulin contains two polypeptide chains, A (21 aa) and B (30 aa), with three disulfide bonds. Two of these interlink the A- and B-chains, while the third one is an intra A-chain bond [4, 5]. Though, initially, insulin was isolated from porcine pancreas, the advent of recombinant DNA technology helped to address the requirement for insulin more effectively. However, commensurate with the projected escalation in the prevalence of diabetes in the coming decades , there will be an increasing demand for insulin. To meet this, more cost-effective biotechnological strategies for recombinant insulin production are required.
Insulin was the first recombinant product approved by the FDA for human application [6, 7]. The first expression systems were based on the separate expression of the A- and B-chains fused to carrier proteins in two different E. coli strains [8, 9]. Nowadays, human insulin is produced as recombinant protein, using two major routes. One route involves the production of an insulin precursor in the form of inclusion bodies, using E. coli as expression host with subsequent solubilization and refolding procedures . The other route involves the utilization of yeast-based expression systems, leading to the secretion of a soluble insulin precursor (IP) into the culture supernatant [11–13]. Both routes are economically viable. Due to the extensive experience in large-scale cultivation, Saccharomyces cerevisiae became the first yeast-based expression system for secretory IP production [11, 12]. Though S. cerevisiae is still the predominant yeast system for insulin production, several alternative yeast hosts have become available in recent years [14–18]. Of these, the methylotrophic yeast Pichia pastoris has emerged as a very useful expression host with superior features [18–21]. In particular, its reliance on integrative vectors, its strong and tightly regulated methanol-inducible alcohol oxidase 1 (AOX1) promoter and its capacity to reach very high cell densities by simple cultivation strategies collectively contribute to stable and high level production of recombinant proteins.
Insulin precursor production with P. pastoris
80 to 90
1 to 0.5
Mut+ (~2) f
For secretory IP production using P. pastoris as host, the S. cerevisiae based α-factor pre-pro leader is most often employed as secretion signal . In general, the insulin B- and A-chains are joined by a short connecting peptide linker, which allows tryptic precursor processing for generation of human insulin [22, 25, 26, 31]. Secretion yields of the single chain insulin precursors can be enhanced by adding a charged synthetic spacer peptide in front of the insulin B-chain segment, which allows more efficient Kex2 endoprotease processing after the α-factor pre-pro leader [13, 22, 32]. After recovery from the culture broth, IP can be converted enzymatically into human insulin [26, 27, 29, 33, 34].
We recently devised a robust cultivation strategy for high-level intracellular production of the Hepatitis B surface antigen (HBsAg), using P. pastoris as expression host . In this procedure, cells were first grown to high-cell density in a batch process, using a simple defined medium with low salt and high glycerol concentrations. After batch growth, induction of high-level product formation was achieved by adding methanol to a final concentration of 6 g L-1 and keeping this high concentration for the remainder of the production phase. In the present work, we have adapted this strategy to secretory IP production. Further, we also present a novel purification procedure, based on the metal binding affinity of IP and, finally, describe the conversion of the insulin precursor to human insulin of high purity by enzymatic and chemical processing.
Construction of the IP-secreting P. pastoris clone
Production of IP in fed-batch culture
Initial attempts for secretory production of IP were based on the direct application of the fed-batch procedure recently developed for high-level intracellular production of HBsAg with P. pastoris. Employing these conditions, cells were first grown in a batch procedure using a simple defined medium with low salt and high glycerol concentrations. After depletion of glycerol, induction of product formation was achieved by adding methanol to a final concentration of 6 g L-1 and keeping this high concentration for the remainder of the production phase. This methanol concentration was very efficient for the intracellular production of HBsAg leading only to minor temporary growth arrest , however, these conditions were detrimental for the secretory production of IP. In this case, addition of methanol to final concentrations of 6 g L-1 was leading to a drastical drop of the optical density concomitant to foam formation indicative of profound cell lysis (data not shown). Moreover, base consumption was replaced by acid consumption indicating the formation and/or release of alkaline compounds. Finally, cultivations had to be discontinued 10-15 h after methanol addition due to uncontrollable foaming.
Purification of IP from the culture broth
Purification of insulin precursor from microbial cultures
E. coli c
Streamline SP (XL)
Expanded bed adsorption
Streamline SP (XL)
Expanded bed adsorption
IMAC-coupled with copper ions
Conversion of IP to human insulin
Purification of insulin precursor by IMAC and conversion to human insulin
Culture broth b
Chelating sepharose FF c
Desalting & Lyophilization
Resource RPC Desalting & Lyophilization
Resource RPC (two passages), Desalting & Lyophilization
The final recombinant human insulin was obtained from pre-insulin by removal of the blocking tertiary butyl groups from threonine in position B30 by acidolysis with trifluoroacetic acid (deprotection reaction). This step was tested at different temperatures (RT, ice, 10°C) and incubation times (from 30 min to 4 h). The highest yields were reached at RT with a reaction time of 60 min. After 60 min, more than 90% of pre-insulin is converted to human insulin (Fig. 4D). Only a minor fraction (~2%) of pre-insulin is converted into undesired by-products such as A21 desamido insulin. Finally, recombinant human insulin was purified by RP-HPLC as described in the Materials and Methods section. During this step, the A21 desamido insulin and other impurities are removed raising the purity of human insulin to 99% as determined by RP-HPLC (Fig. 4E) fully satisfying the European Pharmacopoeia requirements . The total yield of the described process is around 60% (Table 3).
Production of recombinant proteins can be stressful to the host organism . Compared to the intracellular production of HBsAg , the secretory production of IP is more harmful to the cells. Using high methanol concentrations for induction, extensive cell lysis is observed in the case of extracellular IP production but not in the case of the intracellular production of HBsAg. Although the extent of the cellular stress response is influenced by the nature of the recombinant product, membrane damage associated cell lysis is more likely to occur when the recombinant protein is directed towards the extracellular environment compared to intracellular product retention. In case of secretory protein production, less harsh induction conditions might be more advantageous to reduce growth perturbations to acceptable levels while keeping production levels high. For secretory IP production with P. pastoris, induction at a final methanol concentration of 2 g L-1 is appropriate for high level production. This methanol concentration does not cause cell lysis and only leads to a neglectable increase in biomass during the production phase, thus, leading to optimal conditions for the recovery of proteins from the extracellular environment.
In conclusion, a simple two-phase cultivation process composed of a glycerol batch and a constant methanol fed-batch phase was adapted to secretory IP production. This approach increases IP levels more than 2 times compared to the highest previously reported value using Pichia based expression systems. Moreover, we propose a novel procedure to capture the insulin precursor from the culture supernatant using IMAC and, finally, show that ~1.5 g of 99% pure recombinant human insulin can be obtained per liter of culture broth.
Materials and methods
Strains and vectors
P. pastoris host strain X-33 and the plasmid vector pPICZα were purchased from Invitrogen. Plasmid pPICZα (Invitrogen Cat. No. V195-20) was used to construct the methanol inducible IP expression vector. A synthetic codon-optimized gene encoding the IP was inserted into the polylinker of this vector, in-frame with the α-factor secretion signal sequence to create the expression plasmid pPICZα-IP, which was then integrated into the genome of P. pastoris strain X-33. Transformation of Pichia, selection and screening of transformants to identify clones harboring the IP inserts, the isolation of putative multicopy clones using the zeocin screening protocol, and the identification of the methanol utilization (mut) phenotype were performed essentially as described previously .
Culture conditions, control and on-line measurements
Precultures for high-cell density bioreactor cultivations were prepared as described before . High-cell density cultivations were carried out in a 15-L BIOSTAT-C (B. Braun Biotech International, Germany) bioreactor essentially as described previously  with minor modifications. A 1-L preculture was transferred to the bioreactor containing 7 L growth medium. The growth medium contained per liter: glycerol, 95.2 g; potassium di-hydrogen phosphate, 9.4 g; yeast trace metal (YTM) solution, 4.56 g; ammonium sulfate, 15.7 g; magnesium sulfate hepta-hydrate, 4.6 g; calcium chloride di-hydrate, 0.28 g; and biotin, 0.4 mg. The YTM solution contained: potassium iodide, 207.5 mg L-1; manganese sulfate, 760.6 mg L-1; di-sodium molybdate, 484 mg L-1; boric acid, 46.3 mg L-1; zinc sulfate hepta-hydrate, 5.032 g L-1; ferric chloride hexa-hydrate, 12.0 g L-1; and sulfuric acid, 9.2 g L-1. Foaming was controlled by the addition of antifoam (Ucolub N115). Temperature was maintained at 30°C and pH at pH 5.5 with 12.5% (v/v) NH4OH or 1 mol L-1 H3PO4. Aeration rate was maintained at 4 L min-1 throughout the process. The stirrer speed was controlled between 100 to 1370 rpm aiming at a dissolved oxygen (DO) concentration of 20% air saturation. After consumption of glycerol, indicated by an increase of the DO concentration, production of recombinant IP was initiated by step-wise addition of a methanol solution [96.6% (w/w) methanol and 4.4% (w/w) YTM] to a final methanol concentration of 2 g L-1, which was maintained constant throughout the remainder of the induction period based on on-line measured methanol concentrations determined from the methanol vapor in the off-gas using a flame ionization detector (Ratfish Instruments, Germany). Based on the gas liquid phase equilibrium methanol concentrations were determined in the off-gas using two point calibrations directly before and after induction. The concentrations of oxygen and carbon dioxide in the exhaust gas were determined by paramagnetic and infrared exhaust gas analysis systems, respectively (Maihak, Hamburg, Germany).
Determination of cell concentration
The cell concentration of suitably diluted culture samples was measured by optical density (OD) at 600 nm using a Novaspec II spectrophotometer (Pharmacia LKB). For cell dry mass (CDM) determination, 1-mL aliquots of the culture broth were pelleted (13,000 rpm for 15 min at room temperature using an Eppendorf microcentrifuge, model 5415C) in pre-weighed tubes, re-suspended in 50 mmol L-1 phosphate buffer (pH 7.2), re-centrifuged and the resultant pellets vacuum-dried at 80°C (Heraeus Instruments, Vacutherm) to constant mass. CDM was measured in triplicates and averaged.
Determination of glycerol concentration
Culture samples (1-mL) were centrifuged (13,000 rpm for 15 min at 4°C) and the glycerol concentration in the supernatant analyzed in duplicate using glycerol test kits (Roche, Basel, Switzerland).
Clarified culture broth samples were analyzed by denaturing 10%-polyacrylamide gel electrophoresis using the Tricine buffer system . Samples (40-μL) were mixed with an equal volume of loading buffer [250 mmol L-1 Tricine (pH 8.5), 10% β-mercaptoethanol, 2% SDS, 1% glycerol, and 0.1% bromophenol blue], vortexed for 1 min and boiled for 15 min, vortexed again, clarified by centrifugation (max speed, 15 min, RT) and loaded on the gel (20 μL per lane). Following electrophoresis, the separated polypeptides were visualized using Coomassie blue staining.
Reversed-phase HPLC (RP-HPLC) was used for quantification of IP from culture broth. Filtered aliquots of Pichia culture broth (200-μL) were mixed with an equal volume of solution A [0.15% (v/v) TFA in MilliQ water] and analyzed by RP-HPLC using a 3 μm SUPELCOSIL™ LC-304 column (3.3 cm × 4.6 mm) with a Schimadzu liquid chromatography system, equipped with an auto-injector (SIL-10AD VP), UV-VIS detector (SPD-10A), pumps A and B (LC-10AT VP), and a controller (SCL-10A VP). The HPLC column was maintained at 24°C (HPLC column oven, CH-500, Eppendorf, Germany). Elution was done with a gradient formed by mixing solutions A and B [0.15% (v/v) TFA in acetonitrile] as follows: 10% B (0 - 6 min), 10 - 43% B (6 - 41 min), 43 - 100% B (41 - 43 min), 100 - 10% B (43 - 53 min), 10% B (53 - 60 min). The flow rate was maintained at 1 mL min-1. The column effluent was monitored at 280 nm.
Reversed-phase HPLC (RP-HPLC) was also used for characterization and quantification of IP and insulin species after purifications, transpeptidation, and deprotection. These samples were loaded on a 5 μm Phenomenex Jupiter C4 column (300A, 250 mm × 4.6 mm) in solution A [0.1% (v/v) TFA in MilliQ water]. Elution was done at 25°C with a gradient formed by mixing solutions A and B [0.1% (v/v) TFA in acetonitrile] as follows: 0 - 20% B (0 - 6 min), 20 - 55% B (6 - 41 min), 55 - 100% B (41 - 42 min). The flow rate was also 1 mL min-1 and the column effluent was monitored at 280 nm.
Purification of IP using expanded bed absorption
The culture broth (1-L) was diluted with 4 liter of 1% Tween 20 (pH 2.0, 4.7 mS cm-1) to reduce the salt content (conductivity of culture broth was 24.2 mS cm-1), the pH and the viscosity for more efficient binding to the Streamline SP XL resin (Amersham Pharmacia Biotech, Sweden). A Streamline 50 column (Amersham Pharmacia Biotech, Sweden) packed with Streamline SP XL resin to a sedimented height of 13 cm and pre-equilibrated with 1% Tween 20 (pH 2.0; 4.7 mS cm-1) was employed and the diluted and well mixed culture broth was pumped from the lower end of the column leading to an expansion of the sedimented height to 24.4 cm (H/H o expansion ratio = 1.88, where H and H o represent the heights of the column bed after and before expansion, respectively). After loading, the column was washed with MilliQ water (pH 5.8) until the absorbance at 280 nm returned to base line in the eluate. Following, the bound IP was eluted using conventional chromatography by reversing the flow in a now settled bed using 1 mol L-1 NaCl (pH 7.5, conductivity ~100 mS cm-1). Protein containing fractions (absorbance at 280 nm) were pooled and loaded on a preparative C18 bulk column (125 A0 55-105 μm, Waters Corporation, Milford, MA, USA) pre-equilibrated with 10% acetonitrile and 0.1% TFA. After loading, the column was washed with 10% acetonitrile and 0.1% TFA and elution was carried out with 60% acetonitrile and 0.1% TFA. The eluted protein was lyophilized prior to further treatment (Labconco freeze dry system, Germany).
Purification of IP using íon metal affinity chromatography
The culture broth (1-L) was centrifuged (Sorvall RC5BPlus centrifuge, SLA 3000 rotor) at 4°C and 3,000 rpm for 30 min. The supernatant was filtered using a 0.22 μm filter, the pH adjusted to pH 7.0 and the clarified culture supernatant allowed to bind to Cu2+ pre-charged chelating sepharose fast flow (GE Healthcare) pre-equilibrated in equilibration buffer [20 mmol L-1 sodium phosphate buffer (pH 7.0), 500 mmol L-1 NaCl] at room temperature. A maximum of 200 mg IP was used per 50 mL column volume. After sample loading, the column was extensively washed with equilibration buffer to remove unbound proteins. The bound IP was eluted by a linear pH gradient using a low pH elution buffer [20 mmol L-1 sodium phosphate buffer (pH 3.15), 500 mmol L-1 NaCl]. The purified IP was diluted with MilliQ water to lower the conductivity to appr. 8 mS cm-1 and the pH adjusted to pH 4.0 to allow binding to HiTrap SP HP column (GE Healthcare). Elution was performed using 100 mmol L-1 NH4HCO3 (pH 9.0). The purified IP was lyophilized prior to the conversion to pre-insulin by transpeptidation.
Transpeptidation, deprotection and final purification of human insulin
The transpeptidation reaction was essentially performed as described previously  with minor modifications. Briefly, the reaction mixture contained 10 mmol L-1 insulin precursor, 200 μmol L-1 trypsin, 0.8 mol L-1 H-Thr(tBu)-OtBu, 7 mmol L-1 CaCl2, 50% dimethylformamide/ethanol 1:1 (v/v) and 26% water with the pH adjusted to pH 6.0 with acetic acid. The reaction was carried out at 12°C for 24 hrs. The reaction mixture was subjected to semi-preparative gradient chromatography for purification of pre-insulin using a Resource RPC column (GE Healthcare). The bound pre-insulin was eluted by a gradient formed by mixing solutions A (0.2 mol L-1 ammonium sulphate buffer, pH 2.0) and B (0.1 mol L-1 ammonium sulphate buffer with 40% (v/v) acetonitrile) as follows: 0 - 45% B (16.6 column volumes, CV), 45% B (16.6 CV), 45 - 75% B (16.6 CV), 75% B (2.7 CV), 75 - 100% B (3 CV). The purified pre-insulin was desalted by cation exchange chromatography (HiTrap SP HP column, GE Healthcare, elution with 100 mmol L-1 NH4HCO3, pH 9) and lyophilized prior to further processing.
Pre-insulin was transformed to human insulin by removal of the tertiary-butyl groups of threonine in position B30 by acidolysis using trifluoroacetic acid (19 μL TFA per mg pre-insulin). To protect the polypeptide from degradation and desamidation, 0.05 mg each of L-tryptophan and L-glutamine per mg pre-insulin were included as scavengers in the reaction mixture which also contained 2.5% water.
Final purification of human insulin was carried out by semi-preparative gradient chromatography (Resource RPC column, GE Healthcare). The deprotection reaction mixture was subjected to gradient chromatography by mixing solutions A [90% ammonium acetate buffer (1 mol L-1, pH 7.0) and 10% acetonitrile] and B [50% ammonium acetate buffer (1 mol L-1, pH 7.0) and 50% acetonitrile] as follows: 0 - 35% B (1 CV), 35% B (26.6 CV), 35 - 50% B (6 CV), 50% B (6 CV), 50 - 100% B (4 CV). The eluted recombinant human insulin was desalted and lyophilized as described above for long term storage.
Electrospray mass spectrometry (ESI-MS) was performed with API 150EX, PE SCIEX instrument (Applied Biosystems). Samples eluted from Resource RPC columns were desalted (HiTrap SP HP column, GE Healthcare) and lyophilized. Lyophilized samples were reconstituted in 0.1% TFA and 80% acetonitrile in MilliQ water and analyzed by direct infusion (5 μL min-1) in the interval of 600-2500 m/z. Spectra were acquired using LC2Tune 1.4 Software and the molecular mass was obtained by automatic deconvolution using the Biomultiview software.
This work was supported by institutional core funds of ICGEB and Helmholtz Centre for Infection Research and an Indo-German collaborative grant from the Department of Biotechnology, Govt. of India. Ahmad Adnan wishes to express his gratitude to the Higher Education Commission (HEC) of Pakistan for a post-doctoral fellowship. The authors thank Francisco E. Baralle for his support throughout and Guarnaccia Corrado and Zahariev Sotir for mass spectrometry analysis. They also acknowledge the valuable assistance provided by Reinhard Sterlinski, Burkhard Ebert, Maren Michel, Daniela Gebauer, and Poornima Tyagi during different phases of this study.
- Document-WHO/NCD/NCS/99.2: Definition, diagnosis and classification of diabetes mellitus and its complications. World Health Organization. 1999, Accessed on 02.09.2009, http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2.pdf
- Diabetes Fact sheet No 312. World Health Organization. 2008, http://www.who.int/mediacentre/factsheets/fs312/en/
- Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.View Article
- Vajo Z, Fawcett J, Duckworth WC: Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev. 2001, 22: 706-717. 10.1210/er.22.5.706.View Article
- Ahmad B: Pharmacology of insulin. Br J Diabetes Vasc Dis. 2004, 4: 10-14. 10.1177/14746514040040010201.View Article
- Walsh G: Therapeutic insulins and their large-scale manufacture. Appl Microbiol Biotechnol. 2005, 67: 151-159. 10.1007/s00253-004-1809-x.View Article
- Ferrer-Miralles N, Domingo-Espin J, Corchero JL, Vazquez E, Villaverde A: Microbial factories for recombinant pharmaceuticals. Microb Cell Fact. 2009, 8: 17- 10.1186/1475-2859-8-17.View Article
- Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD: Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA. 1979, 76: 106-110. 10.1073/pnas.76.1.106.View Article
- Schmidt M, Babu KR, Khanna N, Marten S, Rinas U: Temperature-induced production of recombinant human insulin in high-cell density cultures of recombinant Escherichia coli. J Biotechnol. 1999, 68: 71-83. 10.1016/S0168-1656(98)00189-8.View Article
- Nilsson J, Jonasson P, Samuelsson E, Ståhl S, Uhlén M: Integrated production of human insulin and its C-peptide. J Biotechnol. 1996, 48: 241-250. 10.1016/0168-1656(96)01514-3.View Article
- Thim L, Hansen MT, Norris K, Hoegh I, Boel E, Forstrom J, Ammerer G, Fiil NP: Secretion and processing of insulin precursors in yeast. Proc Natl Acad Sci USA. 1986, 83: 6766-6770. 10.1073/pnas.83.18.6766.View Article
- Markussen J, Damgaard U, Diers I, Fiil N, Hansen MT, Larsen P, Norris F, Norris K, Schou O, Snel L, Thim L, Voigt HO: Biosynthesis of human insulin in yeast via single chain precursors. Diabetologia. 1986, 29: 568A-569A.
- Kjeldsen T: Yeast secretory expression of insulin precursors. Appl Microbiol Biotechnol. 2000, 54: 277-286. 10.1007/s002530000402.View Article
- Hollenberg CP, Gellissen G: Production of recombinant proteins by methylotrophic yeasts. Curr Opin Biotechnol. 1997, 8: 554-560. 10.1016/S0958-1669(97)80028-6.View Article
- Gellissen G, Hollenberg CP: Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis - a review. Gene. 1997, 190: 87-97. 10.1016/S0378-1119(97)00020-6.View Article
- Romanos M: Advances in the use of Pichia pastoris for high-level gene expression. Curr Opin Biotechnol. 1995, 6: 527-533. 10.1016/0958-1669(95)80087-5.View Article
- Weydemann U, Keup P, Piontek M, Strasser AW, Schweden J, Gellissen G, Janowicz ZA: High-level secretion of hirudin by Hansenula polymorpha - authentic processing of three different preprohirudins. Appl Microbiol Biotechnol. 1995, 44: 377-385. 10.1007/BF00169932.View Article
- Porro D, Sauer M, Branduardi P, Mattanovich D: Recombinant protein production in yeasts. Mol Biotechnol. 2005, 31: 245-259. 10.1385/MB:31:3:245.View Article
- Cereghino GP, Cereghino JL, Ilgen C, Cregg JM: Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr Opin Biotechnol. 2002, 13: 329-332. 10.1016/S0958-1669(02)00330-0.View Article
- Li P, Anumanthan A, Gao XG, Ilangovan K, Suzara VV, Duzgunes N, Renugopalakrishnan V: Expression of recombinant proteins in Pichia pastoris. Appl Biochem Biotechnol. 2007, 142: 105-124. 10.1007/s12010-007-0003-x.View Article
- Macauley-Patrick S, Fazenda ML, McNeil B, Harvey LM: Heterologous protein production using the Pichia pastoris expression system. Yeast. 2005, 22: 249-270. 10.1002/yea.1208.View Article
- Kjeldsen T, Pettersson AF, Hach M: Secretory expression and characterization of insulin in Pichia pastoris. Biotechnol Appl Biochem. 1999, 29: 79-86.
- Mansur M, Cabello C, Hernandez L, Pais J, Varas L, Valdes J, Terrero Y, Hidalgo A, Plana L, Besada V, Garcia L, Lamazares E, Castellanos L, Martinez E: Multiple gene copy number enhances insulin precursor secretion in the yeast Pichia pastoris. Biotechnol Lett. 2005, 27: 339-345. 10.1007/s10529-005-1007-7.View Article
- Pais-Chanfrau JM, Garcia Y, Licor L, Besada V, Castellanos-Serra L, Cabello CI, Hernandez L, Mansur M, Plana L, Hidalgo A, Tambara Y, del CA-P, del TY, Valdes J, Martinez E: Improving the expression of mini-proinsulin in Pichia pastoris. Biotechnol Lett. 2004, 26: 1269-1272. 10.1023/B:BILE.0000044871.80632.f9.View Article
- Pais JM, Varas L, Valdes J, Cabello C, Rodriguez L, Mansur M: Modeling of mini-proinsulin production in Pichia pastoris using the AOX promoter. Biotechnol Lett. 2003, 25: 251-255. 10.1023/A:1022398917213.View Article
- Wang Y, Liang Z-H, Zhang Y-S, Yao S-Y, Xu Y-G, Tang Y-H, Zhu S-Q, Cui D-F, Feng Y-M: Human insulin from a precursor overexpressed in the methylotrophic yeast Pichia pastoris and a simple procedure for purifying the expression product. Biotechnol Bioeng. 2001, 73: 74-79. 10.1002/1097-0290(20010405)73:1<74::AID-BIT1038>3.0.CO;2-V.View Article
- Xie T, Liu Q, Xie F, Liu H, Zhang Y: Secretory expression of insulin precursor in Pichia pastoris and simple procedure for producing recombinant human insulin. Prep Biochem Biotechnol. 2008, 38: 308-317. 10.1080/10826060802165147.View Article
- Zhu T, Guo M, Tang Z, Zhang M, Zhuang Y, Chu J, Zhang S: Efficient generation of multi-copy strains for optimizing secretory expression of porcine insulin precursor in yeast Pichia pastoris. J Appl Microbiol. 2009, 107: 954-963. 10.1111/j.1365-2672.2009.04279.x.View Article
- Ding J-G, Fei J, Cui D-F, Zhang Y-S: Expression of monomeric insulin precursor in Pichia pastoris and its conversion into monomeric B27 Lys destripeptide insulin by tryptic hydrolysis. Acta Biochim Biophys Sin (Shanghai). 2005, 37: 234-240. 10.1111/j.1745-7270.2005.00040.x.View Article
- Gao J-K, Cai S-X, Fan K, Feng Q, Chen H-R, Zhang Y, Hu W, Yang Y-B: Expression of human mini-proinsulin DesB30 in Pichia pastoris and procedure for purifying the expression product. Prog Biochem Biophys. 2009, 35: 63-68.
- Markussen J, Fiil N, Hansen MT, Norris K, Ammerer G, Thim L, Voigt HO: DNA-sequence encoding biosynthetic insulin precursors and process for preparing the insulin precursors and human insulin. US Patent 4, 916, 212. 1990
- Kjeldsen T, Brandt J, Andersen AS, Egel-Mitani M, Hach M, Pettersson AF, Vad K: A removable spacer peptide in an alpha-factor-leader/insulin precursor fusion protein improves processing and concomitant yield of the insulin precursor in Saccharomyces cerevisiae. Gene. 1996, 170: 107-112. 10.1016/0378-1119(95)00822-5.View Article
- Morihara K, Ueno Y, Sakina K: Influence of temperature on the enzymic semisynthesis of human insulin by coupling and transpeptidation method. Biochem J. 1986, 240: 803-810.View Article
- Markussen J: Process for preparing esters of human insulin. US Patent 4, 489, 159. 1984
- Gurramkonda C, Adnan A, Gäbel T, Lünsdorf H, Ross A, Nemani SK, Swaminathan S, Khanna N, Rinas U: Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen. Microb Cell Fact. 2009, 8: 13- 10.1186/1475-2859-8-13.View Article
- Ramesh V, Bradbury JH: 1H NMR studies of insulin: histidine residues, metal binding, and dissociation in alkaline solution. Arch Biochem Biophys. 1987, 258: 112-122. 10.1016/0003-9861(87)90328-6.View Article
- Kaarsholm NC, Ko HC, Dunn MF: Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin. Biochemistry. 1989, 28: 4427-4435. 10.1021/bi00436a046.View Article
- Grant PT, Coombs TL, Frank BH: Differences in the nature of the interaction of insulin and proinsulin with zinc. Biochem J. 1972, 126: 433-440.View Article
- Insulin, human 01/2005:0838. EUROPEAN PHARMACOPOEIA 5.0. 2005, http://www.uspbpep.com/ep50/Insulin,%20human.pdf
- Gasser B, Saloheimo M, Rinas U, Dragosits M, Rodríguez-Carmora E, Baumann K, Giuliani M, Parrilli E, Branduardi P, Lang C, Porro D, Ferrer P, Tutino ML, Mattanovich D, Villaverde A: Conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact. 2008, 7: 11- 10.1186/1475-2859-7-11.View Article
- Vassileva A, Chugh DA, Swaminathan S, Khanna N: Expression of hepatitis B surface antigen in the methylotrophic yeast Pichia pastoris using the GAP promoter. J Biotechnol. 2001, 88: 21-35. 10.1016/S0168-1656(01)00254-1.View Article
- Schägger H, von Jagow G: Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987, 166: 368-379. 10.1016/0003-2697(87)90587-2.View Article
- Brixius P, Mollerup I, Jensen OE, Halfar M, Thommes J, Kula MR: Expanded bed adsorption as a primary recovery step for the isolation of the insulin precursor MI3 process development and scale up. Biotechnol Bioeng. 2006, 93: 14-20. 10.1002/bit.20531.View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.